Latest Breaking News On - Group corporation the company - Page 1 : comparemela.com

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRaman kantSosei heptaresAnita ganjooHironoshin nomuraGenentech rocheCitigate dewe rogersonSosei heptareShinichiro nishishitaSosei group corporationGroup corporation the companySosei groupCorporate communicationsTokyo stock exchangeMedistrava consulting for international media

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomPrnewswire soseiSosei heptaresHironoshin nomuraGenentech rocheTim taskerCitigate dewe rogersonShinichiro nishishitaSosei heptareSosei group corporationGroup corporation the companyBiohaven pharmaceutical holding company ltdSosei groupTokyo stock exchangeMedistrava consulting for international mediaGroup corporation

Sosei Heptares to receive US$2 5 million milestone payment from Formosa Pharmaceuticals

Share this article Share this article TOKYO and CAMBRIDGE, England, March 11, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ( Formosa ) has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa. APP13007 was originally designed and developed at Activus Pharma Inc. ( Activus ), formerly a wholly owned subsidiary of the Company. Activus was divested in August 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories, Inc., a leading manufacturer of Active Pharmaceutical Ingredients ( APIs ) listed on the Taiwan Stock Exchange. The divestment was part of Sosei Heptares redirected growth stra

United kingdomUnited statesPrnewswire soseiSosei heptaresHironoshin nomuraShinichi tamuraStates clinicaltrialsGenentech rocheShinichiro nishishitaCitigate dewe rogersonSosei heptareSosei group corporationInternational mediaGroup corporation the companySosei groupTokyo stock exchange

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

Share this article Share this article TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ( Metrion ), the specialist ion channel CRO and drug discovery company. Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.

United kingdomPrnewswire soseiMetrion biosciencesSosei heptaresRob cookeAndrew southanGenentech rocheMetrion bioscienceSosei heptareSosei group corporationMetrion biosciences limitedGroup corporation the companySosei groupTokyo stock exchangeGroup corporationChief technology officer

Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target

Share this article Share this article TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases. The collaboration will combine Sosei Heptares world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability, with PharmEnable s proprietary advanced artificial intelligence (AI)-enabled and medicinal chemistry technologies (ChemUniverse and ChemSeek) to identify novel, highly specific drug leads for further development.

United kingdomSosei heptaresHironoshin nomuraSue charlesGenentech rocheCitigate dewe rogersonSosei heptareJelena aleksicShinichiro nishishitaSosei group corporationInternational mediaGroup corporation the companyUniversity of cambridgeSosei groupTokyo stock exchangeGroup corporation